To access the full text documents, please follow this link: http://hdl.handle.net/2445/46334

Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR study)
Rubio Valera, Maria; Bosmans, Judith; Fernández Sánchez, Ana; Peñarrubia María, María Teresa; March Pujol, Marian; Travé i Mercadé, Pere; Bellón, Juan A.; Serrano Blanco, Antoni
Universitat de Barcelona
Background: Non-adherence to antidepressants generates higher costs for the treatment of depression. Little is known about the cost-effectiveness of pharmacist's interventions aimed at improving adherence to antidepressants. The study aimed to evaluate the cost-effectiveness of a community pharmacist intervention in comparison with usual care in depressed patients initiating treatment with antidepressants in primary care. Methods: Patients were recruited by general practitioners and randomized to community pharmacist intervention (87) that received an educational intervention and usual care (92). Adherence to antidepressants, clinical symptoms, Quality-Adjusted Life-Years (QALYs), use of healthcare services and productivity losses were measured at baseline, 3 and 6 months. Results: There were no significant differences between groups in costs or effects. From a societal perspective, the incremental cost-effectiveness ratio (ICER) for the community pharmacist intervention compared with usual care was 1,866 for extra adherent patient and 9,872 per extra QALY. In terms of remission of depressive symptoms, the usual care dominated the community pharmacist intervention. If willingness to pay (WTP) is 30,000 per extra adherent patient, remission of symptoms or QALYs, the probability of the community pharmacist intervention being cost-effective was 0.71, 0.46 and 0.75, respectively (societal perspective). From a healthcare perspective, the probability of the community pharmacist intervention being cost-effective in terms of adherence, QALYs and remission was of 0.71, 0.76 and 0.46, respectively, if WTP is 30,000. Conclusion: A brief community pharmacist intervention addressed to depressed patients initiating antidepressant treatment showed a probability of being cost-effective of 0.71 and 0.75 in terms of improvement of adherence and QALYs, respectively, when compared to usual care. Regular implementation of the community pharmacist intervention is not recommended.
Atenció farmacèutica
Atenció primària
Depressió psíquica
Anàlisi cost-benefici
Assaigs clínics
Pharmacy practice
Primary health care
Mental depression
Cost effectiveness
Clinical trials
cc-by (c) Rubio Valera, Maria et al., 2013
http://creativecommons.org/licenses/by/3.0/es
Article
info:eu-repo/semantics/publishedVersion
Public Library of Science (PLoS)
         

Show full item record

Related documents

Other documents of the same author

Rubio Valera, Maria; March Pujol, Marian; Fernández Sánchez, Ana; Peñarrubia María, María Teresa; Travé i Mercadé, Pere; López del Hoyo, Yolanda; Serrano Blanco, Antoni
Rubio Valera, Maria; Serrano Blanco, Antoni; Travé i Mercadé, Pere; Peñarrubia María, María Teresa; Ruiz, Mar; March Pujol, Marian
Rubio Valera, Maria; Serrano Blanco, Antoni; Travé i Mercadé, Pere; Peñarrubia María, María Teresa; Ruiz, Mar; March Pujol, Marian
Rubio Valera, Maria; Serrano Blanco, Antoni; Magdalena Belío, Jesús; Fernández Sánchez, Ana; García Campayo, Javier; March Pujol, Marian; López del Hoyo, Yolanda
March Pujol, Marian; Via Sosa, Ma. de los Ángeles; Rubio Valera, Maria; Roig Martínez, Marta; Travé i Mercadé, Pere; Martínez Castelao, Alberto; Gorris Teruel, José Luis; Alcázar, Roberto (Alcázar Arroyo); Martinez Fernandez, Isabel
 

Coordination

 

Supporters